| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
It is reported that a combined i.v. administration of antigen and IL-2-anti-IL-2 Ab immune complexes (IL-2 ICs) efficiently expands antigen-specific Treg cells in the thymus and induces their migration into peripheral blood. In this study, we explored that the expanded antigen-specific Treg cells rapidly move into the antigen injected site in CCR2 dependent manner. Moreover, prior treatment with antigen and IL-2 ICs enhanced antigen-specific Treg-cell migration and inhibited delayed type hypersensitivity (DTH) reactions. Thus, the treatment with Ag and IL-2 ICs can efficiently expand Ag-specific Treg cells with the capacity to migrate and reduce localized immune responses.
|
